233 related articles for article (PubMed ID: 30669474)
1. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
[TBL] [Abstract][Full Text] [Related]
2. Role of Vonoprazan in
Sugimoto M; Yamaoka Y
Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158
[TBL] [Abstract][Full Text] [Related]
3. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
4. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant
Sue S; Suzuki Y; Sasaki T; Kaneko H; Irie K; Komatsu K; Maeda S
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685510
[TBL] [Abstract][Full Text] [Related]
5. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
[TBL] [Abstract][Full Text] [Related]
6. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of
Mori N; Nishiura Y; Suga D; Moritani I; Yamanaka Y; Ooya Y; Inoue H; Takase K; Hioki M; Shiraki K
Biomed Rep; 2018 Aug; 9(2):169-174. PubMed ID: 30013779
[TBL] [Abstract][Full Text] [Related]
7. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Sue S; Maeda S
Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of
Zhang Z; Liu F; Ai F; Chen X; Liu R; Zhang C; Fang N; Fu T; Wang X; Tang A
Front Pharmacol; 2023; 14():1143969. PubMed ID: 37214450
[No Abstract] [Full Text] [Related]
10. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
11. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Dong SQ; Singh TP; Wei X; Yao H; Wang HL
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
Lin Y; Xu H; Yun J; Yu X; Shi Y; Zhang D
Ann Transl Med; 2022 Sep; 10(18):987. PubMed ID: 36267745
[TBL] [Abstract][Full Text] [Related]
13. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety comparison of
Wang Z; Wang F
Therap Adv Gastroenterol; 2022; 15():17562848221125308. PubMed ID: 36268270
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of
Hojo M; Asaoka D; Takeda T; Shimada Y; Matsumoto K; Matsumoto K; Yatagai N; Akazawa Y; Ueda K; Ueyama H; Nagahara A
Therap Adv Gastroenterol; 2020; 13():1756284820966247. PubMed ID: 33240391
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
18.
Sue S; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
JGH Open; 2021 Feb; 5(2):307-311. PubMed ID: 33553672
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
20. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
